Inositec

Inositec is a biotechnology company developing treatments for soft tissue calcification diseases. Inositec is developing INS-3001 for non-dialysis vascular and cardiovascular calcification diseases, such as CKD-related PAD and aortic valve stenosis (AVS). The company’s lead programs address vascular and renal calcification disorders, including orphan indications. Inositec was founded in December 2015 as a spin-off from ETH Zurich.